Statins are one of the most effective tools we have for reducing cardiovascular risk. They lower LDL cholesterol, stabilize plaque, and significantly reduce the risk of heart attack and stroke.
At the same time, research over the past decade has shown that statins can influence glucose metabolism. Specifically, they are associated with modest increases in insulin resistance and, in some cases, a higher likelihood of developing type 2 diabetes.
This doesn’t mean statins are unsafe. But it does mean there is more to understand about how they affect metabolism—and how to support metabolic health alongside them.
How Statins Affect Blood Sugar at the Cellular Level
Under normal conditions, insulin binds to its receptor on the cell surface, triggering a signaling cascade that ultimately moves GLUT4 transporters to the cell membrane. These transporters act like “gates,” allowing glucose to enter the cell.
Statins work by inhibiting HMG-CoA reductase, which reduces cholesterol production. However, this pathway, known as the mevalonate pathway, also produces important compounds called isoprenoids.
Isoprenoids are required for protein prenylation, a process that allows key signaling proteins to anchor to the cell membrane and function properly. Many of these proteins are directly involved in the insulin signaling pathway that leads to GLUT4 activation and glucose uptake.
When statins reduce isoprenoid production, this process becomes impaired. As a result, insulin signaling is less effective and glucose uptake into the cell is reduced.
Why Statins Can Increase Insulin Resistance
One of the most consistent metabolic effects of statins is an increase in insulin resistance, particularly in adipose tissue.
Inflammatory Signaling and Insulin Resistance
Reduced prenylation activates the NLRP3 inflammasome, a component of the innate immune system. This leads to increased production of interleukin-1β (IL-1β), which interferes with insulin signaling (Henriksbo et al., 2019).
In practical terms:
- Cells become less responsive to insulin
- Glucose uptake into cells decreases
- Blood glucose levels begin to rise
This effect appears to be independent of cholesterol lowering, meaning it is a direct metabolic effect of statin therapy.
Disruption of Intracellular Signaling
Statins also affect intracellular pathways such as p38 MAP kinase and mTOR. These pathways impair Akt phosphorylation, a critical step in how insulin allows glucose to enter cells (Henriksbo et al., 2020).
Together, these changes reduce insulin sensitivity at the cellular level.
Effects on Insulin Secretion
Statins may also affect how much insulin the body produces. Pancreatic β-cells are responsible for insulin secretion, and their function depends on efficient energy production and tightly regulated signaling. Statins can impair β-cell function through multiple mechanisms (Carmena & Betteridge, 2019):
- Reduced cellular energy production
- Increased oxidative stress
- Disrupted intracellular signaling
Over time, this creates a compounding effect:
- The body becomes more insulin resistant
- The pancreas increases insulin output to compensate
- Compensation may eventually fail
At this point, it’s easy to assume that impaired insulin signaling means statins directly cause diabetes. However, this is where the nuance matters. These cellular effects are real, but they do not automatically translate into clinically significant disease for most people.
What This Looks Like in Clinical Studies
These mechanisms are reflected in clinical data.
In a trial using atorvastatin 40 mg daily for 10 weeks:
- Insulin resistance increased by ~8%
- Insulin secretion increased by ~9%
- Overall insulin sensitivity declined
This pattern suggests an early compensatory response that may not be sustainable over time (Abbasi et al., 2021).
How Much Do Statins Raise Blood Sugar?
The effects of statins on blood sugar are generally modest but measurable.
Changes in HbA1c
- Low/moderate-intensity statins: ↑ 0.06–0.09%
- High-intensity statins: ↑ 0.08–0.24%
- In people with diabetes: ↑ 0.1–0.3%
Changes in Fasting Glucose
- Low/moderate intensity: ↑ ~0.7 mg/dL
- High intensity: ↑ ~0.7–4 mg/dL
While these changes are small, they are most relevant in individuals already near diagnostic thresholds (CTT Collaboration, 2024; Newman et al., 2019).
Risk of Developing Type 2 Diabetes
Statin-associated diabetes risk is dose- and duration-dependent (CTT Collaboration, 2024; Newman et al., 2019).
- Low/moderate intensity: ~10% relative increase
- High intensity: ~36% relative increase
However, the absolute risk remains low:
- Approximately 0.2% per year in major trials (Newman et al., 2019)
Longer-term data suggest risk increases with prolonged use, particularly with higher-potency statins (Zhang et al., 2025). This distinction is critical. While relative risk increases are often highlighted, the absolute risk remains small and is largely concentrated in individuals who already have underlying metabolic risk factors. In other words, statins tend to accelerate an existing trajectory rather than create diabetes in otherwise low-risk individuals.
Who Is Most at Risk?
The increased risk is not evenly distributed. It is concentrated in individuals with pre-existing metabolic risk factors (Waters et al., 2013):
- Fasting glucose >100 mg/dL
- Triglycerides >150 mg/dL
- BMI >30
- Hypertension
Individuals without these risk factors appear to have minimal increases in diabetes incidence.
Putting the Risk Into Context
Statins can influence insulin resistance, but they do not inevitably cause diabetes—and for most patients, this distinction is critical. The majority of new-onset diabetes cases occur in individuals who already have elevated fasting glucose, higher triglycerides, or other markers of metabolic dysfunction. In these cases, statins may accelerate progression, but they are not the sole cause.
On the other hand, statins prevent significantly more cardiovascular events than the number of diabetes cases they may contribute to (Newman et al., 2019; Blumenthal et al., 2020).
For most patients:
- The cardiovascular benefit outweighs the metabolic risk
- Statins should not be discontinued due to mild glucose changes
- Monitoring glucose becomes part of routine care
Can Nutrition Help Offset These Effects?
There is limited research specifically targeting statin-induced insulin resistance, but several dietary strategies focused on insulin resistance in general show meaningful benefits.
Mediterranean Diet
In a randomized trial of statin users, statin therapy alone increased insulin levels by 13.2%, while a Mediterranean diet reduced insulin levels by 14%. The combined approach improved insulin sensitivity (Jula et al., 2002).
Carbohydrate Restriction
In individuals taking statins, reducing carbohydrate intake improved insulin sensitivity and led to reductions in triglycerides, insulin levels, blood pressure, and inflammatory markers (Ballard et al., 2013).
Evidence-Based Nutrition Strategies
Even outside statin-specific studies, several strategies consistently improve insulin sensitivity:
- Improve carbohydrate quality (reduce refined carbs, increase fiber) (Weickert, 2012)
- Increase unsaturated fats (olive oil, nuts, fatty fish) (Kirkpatrick et al., 2023)
- Increase total fiber intake (whole grains, legumes, vegetables) (Kirkpatrick et al., 2023)
- Achieve modest weight loss (5–10% improves insulin sensitivity) (Blumenthal et al., 2026)
Bottom Line
Statins can modestly increase insulin resistance and blood glucose through well-defined biological mechanisms involving inflammation, intracellular signaling, and pancreatic function.
However:
- The absolute changes in blood sugar are small
- The increased risk is concentrated in metabolically vulnerable individuals
- The cardiovascular benefits strongly outweigh the risks
The goal is not to avoid statins, but to understand their broader metabolic effects and support metabolic health alongside them—particularly through nutrition and lifestyle strategies that improve insulin sensitivity.
Frequently Asked Questions
Do statins raise blood sugar?
Statins can slightly increase blood sugar levels, but the effect is typically small and varies by individual.
Can statins cause diabetes?
Statins are associated with a modest increase in diabetes risk, particularly in people who already have metabolic risk factors.
Should I stop taking statins if my blood sugar increases?
No. For most individuals, the cardiovascular benefits outweigh the risks. Any changes should be discussed with a healthcare provider.
About the Author
Joseph Lehrberg, MS, RD is a registered dietitian specializing in cardiovascular and metabolic health and founder of CardioFunction Integrative Nutrition Services, a nutrition practice based in Boston. He works with patients with elevated cholesterol, high coronary artery calcium scores, high triglycerides, statin intolerance, and other cardiometabolic risk factors to develop evidence-based nutrition strategies for long-term heart health.
Learn more about working with him here.
References
Abbasi, F., Lamendola, C., Harris, C. S., et al. (2021). Statins are associated with increased insulin resistance and secretion. Arteriosclerosis, Thrombosis, and Vascular Biology.
Ballard, K. D., Quann, E. E., Kupchak, B. R., et al. (2013). Dietary carbohydrate restriction improves insulin sensitivity in individuals taking statins. Nutrition Research.
Blumenthal, R. S., Morris, P. B., Gaudino, M., et al. (2026). ACC/AHA guideline on the management of dyslipidemia. Journal of the American College of Cardiology.
Carmena, R., & Betteridge, D. J. (2019). Diabetogenic action of statins: Mechanisms. Current Atherosclerosis Reports.
Cholesterol Treatment Trialists’ Collaboration. (2024). Effects of statin therapy on new-onset diabetes. The Lancet Diabetes & Endocrinology.
Henriksbo, B. D., Tamrakar, A. K., Xu, J., et al. (2019). Statins promote IL-1β-dependent insulin resistance through reduced prenylation. Diabetes.
Henriksbo, B. D., Tamrakar, A. K., Phulka, J. S., et al. (2020). Statins activate NLRP3 inflammasome and impair insulin signaling. American Journal of Physiology.
Jula, A., Marniemi, J., Huupponen, R., et al. (2002). Effects of diet and simvastatin on insulin and lipids. JAMA.
Kirkpatrick, C. F., Sikand, G., Petersen, K. S., et al. (2023). Nutrition interventions for dyslipidemia. Journal of Clinical Lipidology.
Mansi, I. A., Chansard, M., Lingvay, I., et al. (2021). Statin therapy initiation and diabetes progression. JAMA Internal Medicine.
Newman, C. B., Preiss, D., Tobert, J. A., et al. (2019). Statin safety and adverse events. Arteriosclerosis, Thrombosis, and Vascular Biology.
Waters, D. D., Ho, J. E., Boekholdt, S. M., et al. (2013). Cardiovascular event reduction versus diabetes risk. Journal of the American College of Cardiology.
Weickert, M. O. (2012). Dietary modification and insulin sensitivity. Clinical Endocrinology.
Zhang, Y., Li, Y., Liu, Y., et al. (2025). Duration and type of statin use and diabetes risk. Diabetologia.
